|
1
|
Lima M: Aggressive mature natural killer
cell neoplasms: From epidemiology to diagnosis. Orphanet J Rare
Dis. 8:952013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roman E and Smith AG: Epidemiology of
lymphomas. Histopathology. 58:4–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lim ST, Hee SW, Quek R, Lim LC, Yap SP,
Loong EL, Sng I, Tan LH, Ang MK, Ngeow J, et al: Comparative
analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell
lymphoma: Significant differences in clinical characteristics and
prognosis. Eur J Haematol. 80:55–60. 2008.
|
|
4
|
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY,
Yang SH, Park KW, Kang JH, Park JO, Lee SH, et al: Extranodal nasal
type NK/T-cell lymphoma: Elucidating clinical prognostic factors
for risk-based stratification of therapy. Eur J Cancer.
41:1402–1408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suzuki R: NK/T-cell lymphomas:
Pathobiology, prognosis and treatment paradigm. Curr Oncol Rep.
14:395–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tse E and Kwong YL: Practical management
of natural killer/T-cell lymphoma. Curr Opin Oncol. 24:480–486.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li H, Huang C, Huang K, Wu W, Jiang T, Cao
J, Feng Z and Qiu Z: STAT3 knockdown reduces pancreatic cancer cell
invasiveness and matrix metalloproteinase-7 expression in nude
mice. PLoS One. 6:e259412011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Don-Doncow N, Escobar Z, Johansson M,
Kjellström S, Garcia V, Munoz E, Sterner O, Bjartell A and Hellsten
R: Galiellalactone is a direct inhibitor of the transcription
factor STAT3 in prostate cancer cells. J Biol Chem.
289:15969–15978. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spaccarotella E, Pellegrino E, Ferracin M,
Ferreri C, Cuccuru G, Liu C, Iqbal J, Cantarella D, Taulli R,
Provero P, et al: STAT3-mediated activation of microRNA cluster
17~92 promotes proliferation and survival of ALK-positive
anaplastic large cell lymphoma. Haematologica. 99:116–124. 2014.
View Article : Google Scholar :
|
|
10
|
Koskela HL, Eldfors S, Ellonen P, van
Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ,
Olson T, Jalkanen SE, et al: Somatic STAT3 mutations in large
granular lymphocytic leukemia. N Engl J Med. 366:1905–1913. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sansone P and Bromberg J: Targeting the
interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol.
30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin HO, Lee YH, Park JA, Kim JH, Hong SE,
Kim HA, Kim EK, Noh WC, Kim BH, Ye SK, et al: Blockage of Stat3
enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Biochem Biophys Res Commun. 444:502–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Guo F, Xu G, Ma J and Shao F:
STAT3 cooperates with Twist to mediate epithelial-mesenchymal
transition in human hepatocellular carcinoma cells. Oncol Rep.
33:1872–1882. 2015.PubMed/NCBI
|
|
14
|
Yan CM, Zhao YL, Cai HY, Miao GY and Ma W:
Blockage of PTPRJ promotes cell growth and resistance to 5-FU
through activation of JAK1/STAT3 in the cervical carcinoma cell
line C33A. Oncol Rep. 33:1737–1744. 2015.PubMed/NCBI
|
|
15
|
Munoz J, Dhillon N, Janku F, Watowich SS
and Hong DS: STAT3 inhibitors: Finding a home in lymphoma and
leukemia. Oncologist. 19:536–544. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oh MK, Park HJ, Kim NH, Park SJ, Park IY
and Kim IS: Hypoxia-inducible factor-1alpha enhances haptoglobin
gene expression by improving binding of STAT3 to the promoter. J
Biol Chem. 286:8857–8865. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Liu D, Zhang Y, Zhang H and Cheng
H: The autophagy molecule Beclin 1 maintains persistent activity of
NF-κB and Stat3 in HTLV-1-transformed T lymphocytes. Biochem
Biophys Res Commun. 465:739–745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu ZQ, Han YC, Fang JM, Hu F, Zhang X and
Xu Q: WITHDRAWN: Hypoxia-induced STAT3 contributes to
chemoresistance and epithelial-mesenchymal transition in prostate
cancer cells. Biochem Biophys Res Commun. S0006-291X(15)00244-2.
2015.
|
|
19
|
Horiguchi A and Asano T, Kuroda K, Sato A,
Asakuma J, Ito K, Hayakawa M, Sumitomo M and Asano T: STAT3
inhibitor WP1066 as a novel therapeutic agent for renal cell
carcinoma. Br J Cancer. 102:1592–1599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu K, Chen N, Zhou XX, Ge XL, Feng LL, Li
PP, Li XY, Geng LY and Wang X: The STAT3 inhibitor WP1066
synergizes with vorinostat to induce apoptosis of mantle cell
lymphoma cells. Biochem Biophys Res Commun. 464:292–298. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eiring AM, Page BD, Kraft IL, Mason CC,
Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar
AJ, et al: Combined STAT3 and BCR-ABL1 inhibition induces synthetic
lethality in therapy-resistant chronic myeloid leukemia. Leukemia.
29:586–597. 2015. View Article : Google Scholar :
|
|
22
|
Mills LD, Zhang Y, Marler RJ,
Herreros-Villanueva M, Zhang L, Almada LL, Couch F, Wetmore C,
Pasca di Magliano M and Fernandez-Zapico ME: Loss of the
transcription factor GLI1 identifies a signaling network in the
tumor microenvironment mediating KRAS oncogene-induced
transformation. J Biol Chem. 288:11786–11794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morikawa T, Baba Y, Yamauchi M, Kuchiba A,
Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, et
al: STAT3 expression, molecular features, inflammation patterns,
and prognosis in a database of 724 colorectal cancers. Clin Cancer
Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abou-Ghazal M, Yang DS, Qiao W,
Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W,
Sawaya R, et al: The incidence, correlation with tumor-infiltrating
inflammation, and prognosis of phosphorylated STAT3 expression in
human gliomas. Clin Cancer Res. 14:8228–8235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Groot J, Liang J, Kong LY, Wei J, Piao
Y, Fuller G, Qiao W and Heimberger AB: Modulating antiangiogenic
resistance by inhibiting the signal transducer and activator of
transcription 3 pathway in glioblastoma. Oncotarget. 3:1036–1048.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanterman J, Sade-Feldman M and Baniyash
M: New insights into chronic inflammation-induced
immunosuppression. Semin Cancer Biol. 22:307–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang T, Yuan J, Zhang J, Tian R, Ji W,
Zhou Y, Yang Y, Song W, Zhang F and Niu R: Anxa2 binds to STAT3 and
promotes epithelial to mesenchymal transition in breast cancer
cells. Oncotarget. 6:30975–30992. 2015.PubMed/NCBI
|
|
28
|
Yang C, He L, He P, Liu Y, Wang W, He Y,
Du Y and Gao F: Increased drug resistance in breast cancer by
tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling
pathway. Med Oncol. 32:3522015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iwamaru A, Szymanski S, Iwado E, Aoki H,
Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A
novel inhibitor of the STAT3 pathway induces apoptosis in malignant
glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444.
2007. View Article : Google Scholar
|
|
30
|
Hussain SF, Kong LY, Jordan J, Conrad C,
Madden T, Fokt I, Priebe W and Heimberger AB: A novel small
molecule inhibitor of signal transducers and activators of
transcription 3 reverses immune tolerance in malignant glioma
patients. Cancer Res. 67:9630–9636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meydan N, Grunberger T, Dadi H, Shahar M,
Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, et
al: Inhibition of acute lymphoblastic leukaemia by a Jak-2
inhibitor. Nature. 379:645–648. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Horiguchi A, Oya M, Marumo K and Murai M:
STAT3, but not ERKs, mediates the IL-6-induced proliferation of
renal cancer cells, ACHN and 769P. Kidney Int. 61:926–938. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Judd LM, Menheniott TR, Ling H, Jackson
CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of
the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and
in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ferrajoli A, Faderl S, Van Q, Koch P,
Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W,
et al: WP1066 disrupts Janus kinase-2 and induces caspase-dependent
apoptosis in acute myelogenous leukemia cells. Cancer Res.
67:11291–11299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hatiboglu MA, Kong LY, Wei J, Wang Y,
McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W and Heimberger
AB: The tumor microenvironment expression of p-STAT3 influences the
efficacy of cyclophosphamide with WP1066 in murine melanoma models.
Int J Cancer. 131:8–17. 2012. View Article : Google Scholar :
|
|
36
|
Assi HH, Paran C, VanderVeen N, Savakus J,
Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L,
Mikkelsen T, et al: Preclinical characterization of signal
transducer and activator of transcription 3 small molecule
inhibitors for primary and metastatic brain cancer therapy. J
Pharmacol Exp Ther. 349:458–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
